Drug Discovery World

MARCH 11, 2024

Following a separate submission process the World Health Organization has proposed the International Nonproprietary Name (INN) of cambritaxestat. Cambritaxestat is being developed as a first-in-class therapy for highly fibrotic cancer indications.

Therapies 173

Therapies Drugs FDA International 173

Drug Discovery World

MARCH 12, 2024

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer.

Therapies 130

Therapies Immune Response Licensing Licensing 130

Drug Discovery World

FEBRUARY 23, 2024

Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy programme will be presented at the upcoming 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), taking place March 5-9, 2024, in Lisbon, Portugal.

Therapies 130

Therapies Pharmacokinetics RNA International 130

Drug Discovery World

AUGUST 22, 2022

Three international life sciences start-ups have received investment from the BioInnovation Institute (BII). . Our goal is to harness the untapped potential of European research, and at the BII we are passionate about helping each venture overcome potential hurdles and position them to attract top-quality international investment.

International 130

International Science Hospitals Drug Development 130

Drug Discovery World

MAY 18, 2023

Further projects will automate additional components of ScaleReady’s workflow, such as the robotic movement of G-Rex into and out of incubators. The post Collaboration to simplify cell therapy manufacturing appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Clinical Trials International Trials 130

Drug Discovery World

AUGUST 2, 2022

An international team of researchers has won £30 million for its work in developing a potential cure for inherited heart muscle conditions in young people. . CureHeart is using gene therapy technologies to edit or silence the faulty genes that cause inherited heart muscle diseases. .

International 130

International Research DNA Clinical Trials 130

Drug Discovery World

JUNE 12, 2023

It is the UK’s first specifically designed accessible laboratory for the cell and gene therapy industry. This investment in Scotland builds upon CGT Catapult’s existing work supporting emerging advanced therapy clusters in the UK, with its Manufacturing Innovation Centres in Stevenage, Hertfordshire and Braintree, Essex.

Laboratories 130

Laboratories Therapies Clinical Trials International 130

Drug Discovery World

JUNE 13, 2023

revolution. Designed to automate the manufacturing of advanced therapies without significant process redevelopment, Constellation combines aseptic fluid handling technologies with advanced automation from the industry 4.0 revolution. Cellular Origins’ platform, Constellation has been designed to address this urgent need.

Therapies 130

Therapies Production International Marketing 130

Science Daily: Pharmacology News

JUNE 5, 2024

A new clinical trial of five children with inherited deafness found administering gene therapy in both ears led to restored hearing and speech, and additional gains including sound source localization, ability to hear in noisy environments, and for two children, abillity to appreciate music.

Therapies 104

Therapies Trials Clinical Trials International 104

Drug Discovery World

NOVEMBER 14, 2023

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). The post First therapy for very rare blood clotting disorder gets US greenlight appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies FDA Approval Protein Production FDA 130

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 138

Therapies DNA Virus Clinical Trials 138

Drug Discovery World

MARCH 16, 2023

The cell and gene therapy (CGT) market is rapidly expanding, and projections suggest it will reach over $90B by 2023. Challenges of cell and gene therapy manufacturing Compared to traditional biologics, CGTs are living drugs, making their development and manufacturing substantially more complex.

Therapies 130

Therapies FDA Approval Science Production 130

Drug Discovery World

AUGUST 29, 2023

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. The data were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

Therapies 130

Therapies Clinical Trials Trials Disease 130

Drug Discovery World

DECEMBER 4, 2023

The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. The post DNA therapy effective against chemo-resistant ovarian cancer appeared first on Drug Discovery World (DDW).

DNA 147

DNA Therapies Packaging Vaccine 147

Drug Discovery World

FEBRUARY 23, 2024

Efficacy was evaluated in the Phase III trial FLAURA2 in 557 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive la/mNSCLC and no prior systemic therapy for advanced disease. The post Combination therapy reduced risk of lung cancer progression by 38% appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies FDA Trials Treatment 130

Drug Discovery World

MARCH 2, 2023

The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of the company’s cancer drug pipeline and the latest innovations in targeted oncology.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

MAY 5, 2023

Efforts to fulfil the promise of precision medicine, including the use of targeted cancer therapies, necessitate that patients be treated based on the specific genetic alterations that drive their individual cancers. But what about the patients whose genomic tests do not identify a cancer driver matched to an existing targeted therapy?

Therapies 130

Therapies RNA Research Pharmaceutical Companies 130

Drug Discovery World

SEPTEMBER 16, 2022

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.

Therapies 130

Therapies Licensing Licensing Clinical Research 130

Drug Discovery World

FEBRUARY 22, 2023

The post EU-approved gene therapy reduced haemophilia bleeds by 64% appeared first on Drug Discovery World (DDW). The treatment was approved by the US Food and Drug Administration in November 2022.

Therapies 130

Therapies Clinical Trials Licensing Licensing 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? Curbishley explains that as the wave of new therapies in development continues to increase, global pressures on manufacturing availability will become more acute.

Therapies 130

Therapies Clinical Trials Marketing Production 130

Drug Discovery World

APRIL 18, 2023

The AcSé-ESMART trial AcSé-ESMART is an international European proof-of-concept platform trial intended to match paediatric, adolescent, and young adult patients with relapsed or treatment-refractory cancers with a treatment regimen targeted to their cancer’s mutational profile.

Therapies 130

Therapies DNA Trials RNA 130

DrugBank

JUNE 13, 2024

Unlike traditional oral medications with limited bioavailability and potential for erratic absorption, IDDS function as internal drug repositories, delivering precise doses of medication directly at the site of action or into the systemic circulation via precisely adjusted release mechanisms. 

Therapies 76

Therapies Drugs DNA Engineering 76

Drug Discovery World

APRIL 17, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will detail how Oxford Nanopore evaluated long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs which is supporting internal research activities at AstraZeneca.

DNA 246

DNA Packaging Virus International 246

Drug Discovery World

JANUARY 10, 2024

Speaking on the recent FDA statement, Bruce Levine, ISCT Immediate Past President and Lead Author on the publication, stated: “The fundamental question from this report is whether or not there is a causal link between CAR-T therapy and these rare T cell malignancy cases and in how many patients.

FDA 147

FDA Therapies International Treatment 147

On Medicine

SEPTEMBER 21, 2023

The direct mechanisms include inhibition of DNA replication and regeneration of mucosal cells by anticancer therapy. The World Association of Photobiomodulation Therapy (WALT) group outlined the evidence and prescribed the potential prophylactic and therapeutic effects of PBM on the side effects of cancer therapy.

Therapies 82

Therapies Treatment DNA International 82

Drug Discovery World

FEBRUARY 13, 2024

The UK’s Education Secretary Gillian Keegan attended a meeting with the Cell and Gene Therapy Catapult (CGT Catapult) to discuss the role of apprenticeships in the advanced therapies industry. The ATAC programme, which was set up in 2018, is designed to train individuals to work in the advanced therapies industry.

Therapies 130

Therapies International Science Government 130

Drug Target Review

FEBRUARY 13, 2024

In light of the International Day of Women and Girls in Science, which celebrates the achievements of women in STEM, could you share an example of a project or research that has been particularly impactful within your field? I started my career in the early stages of the targeted approach to drug therapies.

International 58

International Science Engineering Research 58

Drug Discovery World

JULY 14, 2023

awarded to progress ovarian cancer cell therapy NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. £1m awarded to progress ovarian cancer cell therapy NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. £1m

International 130

International DNA Pharmaceutical Companies Therapies 130

Drug Discovery World

APRIL 16, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will highlight how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca.

Packaging 130

Packaging DNA Virus International 130

Drug Discovery World

JUNE 22, 2023

According to ARM, all seven gene therapies for rare genetic diseases would have been rejected under the baseline methodologies proposed for the EU joint clinical assessment (JCA) starting in 2025.

Clinical Trials 237

Clinical Trials Therapies Disease Trials 237

Drug Discovery World

DECEMBER 1, 2023

The top stories: Potential disease-modifying therapy for Parkinson’s disease An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications.

Therapies 130

Therapies Drugs International Disease 130

Drug Discovery World

JUNE 13, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. Here, attendees discuss the trend of allo vs auto.

Therapies 246

Therapies Medical Schools Production Clinical Trials 246

Drug Discovery World

MAY 1, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will detail how Oxford Nanopore evaluated long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs which is supporting internal research activities at AstraZeneca.

Packaging 130

Packaging DNA Virus International 130

Drug Discovery World

JULY 3, 2024

SMEs are vital both to the economic growth of the UK and to the patients who ultimately benefit from the innovative therapies that make it to market. We have the talent, but if it is not nurtured we risk losing ground to international competitors and worse, failing to deliver innovative pipelines that can treat patients.

Government 147

Government Drugs Science International 147

Drug Discovery World

APRIL 24, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will detail how Oxford Nanopore evaluated long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs which is supporting internal research activities at AstraZeneca.

DNA 130

DNA Packaging Virus International 130

Drug Discovery World

FEBRUARY 2, 2024

Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of a rare blood cancer drug and a novel production process for CAR-T therapies.

Pharmacokinetics 130

Pharmacokinetics International Clinical Trials Drugs 130

Drug Discovery World

JANUARY 18, 2024

Market opportunity estimated at over US$1 billion Largely due to the CRS risk (which can be life threatening), administration of cancer immunotherapies, such as bispecific antibodies, is currently restricted to specialist cancer centres which limits uptake of these therapies.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162